Literature DB >> 24376526

Vitamin D receptor, an important transcription factor associated with aldosterone-producing adenoma.

Changlong Bi1, Bo Li1, Lili Du1, Lishan Wang2, Yingqi Zhang1, Zhifeng Cheng1, Aixia Zhai3.   

Abstract

OBJECTIVE: To explore the endocrine mechanisms of aldosterone-producing adenoma (APA) by using the microarray expression profiles of normal and APA samples.
METHODS: The gene expression profile GSE8514 was downloaded from Gene Expression Omnibus database, including samples from normal adrenals (n = 5) and APAs (n = 10). The differentially expressed genes (DEGs) were identified by samr package and endocrine DEGs were obtained according to Clinical Genome Database. Then, functional enrichment analysis of screened DEGs was performed by DAVID (Database for Annotation, Visualization and Integrated Discovery). Finally, a regulatory network was constructed to screen endocrine genes related with adrenal dysfunction and pathway enrichment analysis for the constructed network was performed.
RESULTS: A total of 2149 DEGs were identified including 379 up- and 1770 down-regulated genes. And 26 endocrine genes were filtered from the DEGs. Furthermore, the down-regulated DEGs are mainly related to protein kinase cascade, response to molecule of bacterial origin, response to lipopolysaccharide, cellular macromolecule catabolic process and macromolecule catabolic process, while the up-regulated DEGs are related with regulation of ion transport. The target genes of VDR (vitamin D receptor), one of the three endocrine genes differentially expressed in the regulatory network, were endocrine genes including CYP24A1 (25-hydroxyvitamin D-24-hydroxylase) and PTH (parathyroid hormone). Three pathways may be associated with APA pathogenesis including cytokine-cytokine receptor interaction, pathways in cancer and autoimmune thyroid disease.
CONCLUSION: The VDR is the most significant transcription factor and related endocrine genes might play important roles in the endocrine mechanisms of APA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24376526      PMCID: PMC3869669          DOI: 10.1371/journal.pone.0082309

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Primary Aldosterone disease is a major cause of secondary hypertension and characterized by overproduction of the mineralocorticoid hormone aldosterone [1,2]. The inappropriately high production of aldosterone can lead to suppression of plasma renin, sodium retention, hypertension, cardiovascular damage, and potassium excretion [3]. There are two main subtypes of primary aldosterone: unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA) [4,5]. APA, which typically diagnosed between ages 30 and 70, are accounts for about 30% of hyperaldosteronism and the degree of hyperaldosteronism is greater than that in IHA [6]. Recent recommendations have suggested that the aldosterone to renin ratio and adrenal computed tomography can be used to screen for the prevalence of APA [7]. APA virtually always remains benign, without local invasion or distant metastasis [8]. In the large majority of patients, surgical removal may also ameliorate hypertension caused by APA. Several studies have suggested that the overproduction of steroid hormones in adrenocortical tumors might be resulted from the disordered expression of steroidogenic enzymes, such as aldosterone synthase (CYP11B2) [9]. The expression level of CYP11B2 is significantly higher in APA [10]. The somatic mutation in two members of the ATPase gene family can result in autonomous aldosterone secretion [11]. Somatic mutations of cardiac ATP-sensitive potassium channel gene (KCNJ5), coding for the G protein-coupled inward rectifier K+ channel 4, have been implicated in the formation of APA while are recently proved not correlated with adrenal cortex remodeling [12]. Some evidence has showed that the calcium-binding calmodulin kinase (CAMK) signaling pathway is involved in human APA [13]. CAMKs can regulate the production of angiotensin II- and potassium-stimulated aldosterone. CYP11B2 transcription could be mediated by CAMK-I via cyclic adenosine monophosphate response element binding protein and the activation of transcription factor 1 and Nur-related factor 1 [14]. To date, although the genetic basis of hyperaldosteronism has been more clearly, the exact endocrine pathogenesis of the disease still remains unknown. In the present study, we downloaded the gene expression profiles of APA specimens and normal samples. The differentially expressed genes (DEGs) and endocrine DEGs were identified. Then the function enrichment analysis of DEGs was applied to gain more insight into the molecule mechanisms of APA. In addition, we built transcription factor (TF)-target regulatory network and the pathway enrichment analysis of the network was performed to find the dysfunction endocrine genes and pathways in APA.

Materials and Methods

Derivation of genetic data and data preprocessing

The gene expression profile of GSE8514 [15] containing 15 specimens was downloaded from a public functional genomics data repository Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) database. The 15 specimens, including 5 normal samples from normal human adult adrenal glands and 10 APA specimens from Conn’s syndrome patients were available based on the Affymetrix Human Genome U133 Plus 2.0 Array. The original files were converted into expression measures matrix by the robust multiarray average (RMA) algorithm with defaulted parameters in Affy package in the R software [16]. Then the R/Bioconductor annotation package was used to convert probe number to gene ID. For each sample, the expression values of all probes for a given gene were reduced to a single value by taking the average expression value.

Identification of differentially expressed genes and endocrine genes

The samr package in R software [17] was used to identify differentially expressed genes between normal and APA samples. The false discovery rate (FDR) <0.05 and fold change ≥1.5 were used as the cut-off criteria [18]. For hierarchical clustering of samples and screened DEGs, clustering algorithm based upon Pearson and Spearman correlations were used to create a clustering graph of samples and genes in which samples and genes with similar expression pattern are grouped together [19]. In order to make sure that DEGs were correctly screened, the APA samples clustered with normal samples were removed and DEGs were further identified between the normal samples and the rest APA samples. What’s more, the differentially expressed endocrine genes associated with APA were filtered from Clinical Genome Database (CGD, ) [20].

Functional enrichment analysis of DEGs

Gene Ontology (GO) analysis has become a common approach for functional annotation of large-scale genomic data [21]. DAVID (Database for Annotation, Visualization and Integrated Discovery) provides an integrated biological knowledgebase and analytic tools for researchers to systematically extract biological meaning from large list of genes/proteins [22]. The functional GO enrichment analysis for the screened up-regulated and down-regulated DEGs was performed by DAVID online, respectively. The FDR<0.05 was chosen as the cut-off criterion.

TF-target regulatory network construction and pathway enrichment analysis

TRANSFA (Transcription Factor Database) is a database about the eukaryotic transcriptional regulation which contains data on eukaryotic transcription factors, their regulatory binding sites, binding sequences and target genes [23-25]. The DEGs were mapped to known regulatory data between transcription factors and target genes, then a TF-target regulatory network was constructed by Cytoscape [26]. And the regulatory impact factors of each transcription factor were calculated to screen out endocrine genes related with adrenal dysfunction. Then DAVID online was applied for KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment of the nodes of TF-target regulatory network and adrenal abnormal pathways were selected for further analysis. The FDR<0.05 was chosen as the cut-off criterion. KEGG is a databases consisted of genomic information, chemical information and biological systems information [27].

Results

Identification of DEGs and endocrine genes

From the hierarchical clustering of samples and genes, we found that total 4 APA samples in red boxes (Figure S1) were clustered with normal samples according to the clustering graph. After removing the 4 APA samples which clustered with normal adrenal samples, we applied the samr package to further identify genes differentially expressed between 5 normal samples and the rest 6 APA samples. For dataset GSE8514, a total of 2149 DEGs were identified, including 379 up-regulated genes and 1770 down-regulated genes (Figure 1). The top 10 up- and down-regulated DEGs were listed in Table 1.
Figure 1

Clustering graph of the differentially expressed genes identified from 5 normal samples and 6 aldosterone producing adenoma samples.

The horizontal axis is the sample names and the right vertical axis represents the genes. The left vertical axis represents the genes cluster; the top horizontal axis represents the sample cluster. The green color stands for up-regulated genes, while the red color stands for down-regulated genes.

Table 1

The top 10 up-regulated (red) and down-regulated (green) DEGs in aldosterone producing adenoma samples.

Gene symbolFold changeExpression change
CYP11B269.75006657up
VPREB310.60896188up
PCP48.876766496up
MT36.7543199up
HHATL5.017961155up
SLC24A34.86500277up
FAM19A44.770089027up
IL17D3.048374974up
SUSD22.976578974up
NMRK22.939796564up
FAM172A0.666634down
PSMG20.666602down
LOC2858120.666395down
MST40.666187down
PEX190.66606down
ABHD14B0.665784down
C5orf40.665743down
SLC35B30.665573down
FSTL50.665486down
NAALAD20.665475down

Clustering graph of the differentially expressed genes identified from 5 normal samples and 6 aldosterone producing adenoma samples.

The horizontal axis is the sample names and the right vertical axis represents the genes. The left vertical axis represents the genes cluster; the top horizontal axis represents the sample cluster. The green color stands for up-regulated genes, while the red color stands for down-regulated genes. There are 154 abnormally expressed genes in endocrine diseases are associated with clinical features in CGD. A total of 26 endocrine genes were filtered from the DEGs, such as CYP11B2 (aldosterone synthase), VDR (vitamin D receptor), POR (P450 oxidoreductase), KCNJ5 (cardiac ATP-sensitive potassium channel gene), RET (protein receptor tyrosine kinase) andCYP11B1 (11β-hydroxylase gene). The functional enrichment analysis of DEGs was performed by DAVID with FDR<0.05. As shown in the Table 2, a total 6 GO terms of up- and down- regulated DEGs were obtained. The down-regulated genes mainly related with 5 GO terms, such as protein kinase cascade (FDR=2.67E-04), response to molecule of bacterial origin (FDR=7.35E-04), response to lipopolysaccharide (FDR=0.0014288), cellular macromolecule catabolic process (FDR=0.0137273) and macromolecule catabolic process (FDR=0.0149602). On the other hand, the up-regulated genes were significantly related to the regulation of ion transport (FDR=0.0200308).
Table 2

Gene ontlogy (GO) enrichment items of the up- and down-regulated DEGs.

TypeGO TermGene CountFold EnrichmentFDR
Down-regulated genesGO:0007243~protein kinase cascade661.9618721162.67E-04
GO:0002237~response to molecule of bacterial origin253.1972017397.35E-04
GO:0032496~response to lipopolysaccharide233.2852285930.0014288
GO:0044265~cellular macromolecule catabolic process1021.5473574430.0137273
GO:0009057~macromolecule catabolic process1081.5209019080.0149602
Up-regulated genesGO:0043269~regulation of ion transport107.0075110080.0200308
A total of 29 transcription factors were obtained by mapping the DEGs to known 6,001 pairs of transcription factors-target genes. Then we constructed APA differentially expressed transcription factor-target gene networks based on the 29 transcription factors (Figure S2). The network was consisted of 429 nodes and 522 pairs of transcription factors-target genes. We found 19 endocrine genes in this network, such as VDR, CYP24A1 (25-hydroxyvitamin D-24-hydroxylase), POR, PTH (parathyroid hormone), RET and TPO (thyroid peroxidase). While only three endocrine genes (VDR, POR, RET) were differentially expressed in APA samples, other 16 genes were target genes of differentially expressed transcription factors. Since the downstream genes of VDR were endocrine genes (CYP24A1, PTH), VDR was a very significant transcription factors. ETS1 (E26 transformation-specific 1), EGR1 (early growth response 1) and CEBPB (CCAAT/enhancer-binding protein beta) were considered as the hub genes in this network which indicated that these three genes had a highly correlation with the APA. Furthermore, the non-DEGs (blue circles) in the Figure S2 were removed so that the other nodes (green or red diamonds; green or red circles) can stand out and more legible (Figure 2). It is worth noting that some nodes only related with non-DEGs could not be reflected in the figure since the blue circles were removed.
Figure 2

The constructed differentially expressed transcription factor-target gene network without non-differentially expressed target genes.

To gain further insights into the signaling pathways in the process of APA, pathway enrichment analysis for the constructed TF-target regulatory network was performed by the online biological classification tool DAVID. A total of 19 KEGG pathways were enriched with the criterion of FDR<0.05 (Table 3). There are three pathways may be associated with APA including hsa04060: Cytokine-cytokine receptor interaction (FDR=7.22E-16), hsa05200: Pathways in cancer (FDR=3.03E-14) and hsa05320: Autoimmune thyroid disease (FDR=0.0044084).
Table 3

The enriched KEGG pathways of aldosteronoma Transcription Factor (TF)-target network (the pathways marked in red may be associated with the process of aldosteronoma).

KEGG pathwayGene CountAdjusted p-value   FDR
hsa04640:Hematopoietic cell lineage336.11E-194.92E-18
hsa04060:Cytokine-cytokine receptor interaction528.96E-177.22E-16
hsa05200:Pathways in cancer563.77E-153.03E-14
hsa04630:Jak-STAT signaling pathway353.55E-122.86E-11
hsa05215:Prostate cancer231.49E-081.20E-07
hsa05219:Bladder cancer156.19E-074.99E-06
hsa04510:Focal adhesion312.85E-062.29E-05
hsa04115:p53 signaling pathway171.26E-051.01E-04
hsa05220:Chronic myeloid leukemia175.39E-054.34E-04
hsa05330:Allograft rejection128.24E-056.64E-04
hsa05210:Colorectal cancer172.72E-040.0021882
hsa04940:Type I diabetes mellitus124.53E-040.0036484
hsa05320:Autoimmune thyroid disease135.47E-040.0044084
hsa04620:Toll-like receptor signaling pathway187.67E-040.0061796
hsa05310:Asthma107.93E-040.0063887
hsa05218:Melanoma157.97E-040.0064204
hsa05332:Graft-versus-host disease110.00158720.0127864
hsa05212:Pancreatic cancer140.00470220.0379345
hsa05222:Small cell lung cancer150.00595740.0480882

Discussion

Aldosterone producing adenomas is one of the most common forms of surgically curable hypertension [28]. To further understand endocrine mechanisms involved in APA formation, we investigated the biological processes and signaling pathways related with APA. In this work, 2149 DEGs were identified including 379 up-regulated genes and 1770 down-regulated genes. The down-regulated DEGs are mainly related to protein kinase cascade, response to molecule of bacterial origin, response to lipopolysaccharide, cellular macromolecule catabolic process and macromolecule catabolic process, while the up-regulated DEGs are related with regulation of ion transport. Studies have shown that sodium/potassium-transporting ATPase subunit alpha-1 is an enzyme encoded by the ATP1A1 gene [29], and mutations in this gene have been associated with APAs and secondary hypertension. Three major pathogenetic pathways including lipopolysaccharide/Toll like receptor 4 pathway are novel pathological mechanisms of adrenocortical tumors and associated genes may be markers and therapeutic targets of malignancy [30]. Through filtering the DEGs from Clinical Genome Database, we obtained 26 differentially expressed endocrine genes, such as CYP11B1, CYP11B2 and KCNJ5. The cortisol and aldosterone in human adrenal cortex are synthesized by the isozymes 11β-hydroxylase and aldosterone synthase, encoded by the 93% identical CYP11B1 and CYP11B2 genes, respectively [31]. A CYP11B2 haplotype including 344T and K173 polymorphism is associated with higher gene expression, higher aldosterone production and blood pressure in the APA patients [32]. Mutations in the KCNJ5 gene can produce increased Na+ conductance in a mendelian form of severe aldosteronism and massive bilateral adrenal hyperplasia [8]. KCNJ5 mutations are prevalent in APA, and KCNJ5 mutations can increase expression of CYP11B2 and NR4A2 (nuclear receptor subfamily 4, group A, member 2), thus increasing aldosterone production [33]. In our study, a TF-target regulatory network was constructed and there were 19 endocrine genes in the network. Only VDR, POR and RET are differentially expressed in APA specimens. POR serves as electron donor to steroidogenic cytochrome P450 (CYP) type II enzymes. Inactivating mutations in POR gene is responsible for the congenital adrenal hyperplasia (CAH) manifesting with apparent combined CYP17A1-CYP21A2 deficiency [34]. The RET gene is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma which encodes a single-pass transmembrane receptor tyrosine kinase[35]. VDR is a very significant transcription factor associated with APAs and its target genes (CYP24A1 and PTH) are endocrine genes. These results suggested that, the correlation between differentially expressed endocrine genes and transcription factors is not significant in APA patients, and the abnormal expression of endocrine transcription factor in APA samples does not necessarily lead to the abnormal expression of endocrine gene [36]. The regulated genes, such as VDR, modulated by angiotensin II increased expression for both 11β-hydroxylase and aldosterone synthase, which indicated that the modulated transcription regulatory genes may be related with adrenal steroidogenesis pathologies [37]. Vitamin D deficiency is traditionally recognized as a key factor in the bone and mineral disturbances of chronic kidney disease (CKD) [38]. Vitamin D response element (VDRE2) variant can result in the decrease of CYP24A1 (a gene that is highly inducible by 1α,25(OH)2D3) expression in cultured primary human lymphocytes [39]. Parathyroid hormone acts to increase the concentration of calcium in the blood. Kong et al. found that suppression of renin expression by 1α,25(OH)2D3 in vivo is independent of PTH and calcium[40]. ETS1, EGR1 and CEBPB are considered as the hub genes in the constructed TF-target regulatory network. Observations suggest that locally produced ETS may closely involve in the regulation of corticosteroid secretion and mitogenesis in normal and tumoral adrenocortical cells [41]. Ca2+ transporter (Atp2a3), one of the target genes of ETS, showed an enrichment in the zona glomerulosa (zG) [42]. The ability of APA and zG to produce aldosterone would suggest some similarities in transcript expression patterns including a trend of up-regulation in Atp2a3 in both rat zG and human APA [43]. Furthermore, the KEGG pathway enrichment of the TF-target regulatory network was performed. And we selected three pathways which might be related with APA: (i) cytokine-cytokine receptor interaction; (ii) pathways in cancer; (iii) autoimmune thyroid disease. Cytokines (http://www.ncbi.nlm.nih.gov/biosystems/460) are soluble proteins, peptides or glycoproteins which are crucial signaling molecules or intercellular regulators of cells engaged in innate and adaptive inflammatory host defenses aimed at maintaining homeostasis. TGF-β signaling pathway is important for the proliferation of intrarenal fibroblasts and the epithelial–mesenchymal transition through which tubular cells become fibroblasts [44]. Asmah et al. have showed that regulation of renin was mainly influenced by free triiodothyronine (T3), and that aldosterone response to frusemide was blunted in thyrotoxicosis despite normal electrolytes [45]. In summary, the VDR is the most significant transcription factor screened from the TF-target regulatory network and its target genes including CYP11B2 and KCNJ5 might play important roles in the endocrine mechanisms of APA. Meanwhile, several pathways maybe involve in the progression of APA, such as cytokine-cytokine receptor interaction, pathways in cancer and autoimmune thyroid disease. However, further studies still needed to confirm our results. The hierarchical clustering of samples and screened DEGs. Total 4 APA samples including Ald.10, Ald.3, Ald.6 and Ald.4 (red boxes) were clustered with normal samples. (TIF) Click here for additional data file. The constructed differentially expressed transcription factor-target gene network. The network consists of 429 nodes and 522 pairs of transcription factor-target gene. The diamond nodes stand for the known transcription factors that differentially expressed in aldosteronoma samples (29). Circular nodes are the target genes of transcription factors (400). The green circle nodes are differentially expressed target genes in aldosteronoma samples (46), the red nodes are the known endocrine genes (19). The light blue circle nodes stand for non-differentially expressed target genes (336). (TIF) Click here for additional data file.
  45 in total

1.  Primary aldosteronism in general practice.

Authors:  N N Chan; A J Isaacs
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

2.  Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells.

Authors:  Silvia Monticone; Namita G Hattangady; Koshiro Nishimoto; Franco Mantero; Beatrice Rubin; Maria Verena Cicala; Raffaele Pezzani; Richard J Auchus; Hans K Ghayee; Hirotaka Shibata; Isao Kurihara; Tracy A Williams; Judith G Giri; Roni J Bollag; Michael A Edwards; Carlos M Isales; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2012-05-24       Impact factor: 5.958

3.  Association of Lys173Arg polymorphism with CYP11B2 expression in normal adrenal glands and aldosterone-producing adenomas.

Authors:  Hiromichi Tanahashi; Tomoatsu Mune; Yoshito Takahashi; Mako Isaji; Tetsuya Suwa; Hiroyuki Morita; Noriyoshi Yamakita; Keigo Yasuda; Takashi Deguchi; Perrin C White; Jun Takeda
Journal:  J Clin Endocrinol Metab       Date:  2005-08-23       Impact factor: 5.958

4.  Clinical genomic database.

Authors:  Benjamin D Solomon; Anh-Dao Nguyen; Kelly A Bear; Tyra G Wolfsberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-21       Impact factor: 11.205

5.  Role for adrenal venous sampling in primary aldosteronism.

Authors:  William F Young; Anthony W Stanson; Geoffrey B Thompson; Clive S Grant; David R Farley; Jon A van Heerden
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

6.  Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed.

Authors:  P M Szabó; V Tamási; V Molnár; M Andrásfalvy; Z Tömböl; R Farkas; K Kövesdi; A Patócs; M Tóth; C Szalai; A Falus; K Rácz; P Igaz
Journal:  Oncogene       Date:  2010-03-22       Impact factor: 9.867

7.  K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.

Authors:  Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

Review 8.  Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.

Authors:  William F Young
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

9.  Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis.

Authors:  Livia Lenzini; Teresa M Seccia; Enrico Aldighieri; Anna S Belloni; Paolo Bernante; Luisa Giuliani; Gastone G Nussdorfer; Achille C Pessina; Gian Paolo Rossi
Journal:  Hypertension       Date:  2007-10-15       Impact factor: 10.190

10.  Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene.

Authors:  P Mulatero; F Veglio; C Pilon; F Rabbia; C Zocchi; P Limone; M Boscaro; N Sonino; F Fallo
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more
  4 in total

1.  Effect of Dietary Sodium Modulation on Pig Adrenal Steroidogenesis and Transcriptome Profiles.

Authors:  Twinkle Vohra; Elisabeth Kemter; Eckhard Wolf; Tracy Ann Williams; Na Sun; Britta Dobenecker; Arne Hinrichs; Jacopo Burrello; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez; Jun Wang; Isabella-Sabrina Kinker; Daniel Teupser; Konrad Fischer; Angelika Schnieke; Mirko Peitzsch; Graeme Eisenhofer; Axel Walch; Martin Reincke
Journal:  Hypertension       Date:  2020-10-19       Impact factor: 10.190

Review 2.  Adrenal disorders: Is there Any role for vitamin D?

Authors:  Giacomo Tirabassi; Gianmaria Salvio; Barbara Altieri; Cristina L Ronchi; Silvia Della Casa; Alfredo Pontecorvi; Giancarlo Balercia
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

3.  Hypomethylation associated vitamin D receptor expression in ATP1A1 mutant aldosterone-producing adenoma.

Authors:  Yuta Nanao; Kenji Oki; Kazuhiro Kobuke; Kiyotaka Itcho; Ryuta Baba; Takaya Kodama; Yu Otagaki; Akira Okada; Yoko Yoshii; Gaku Nagano; Haruya Ohno; Koji Arihiro; Celso E Gomez-Sanchez; Noboru Hattori; Masayasu Yoneda
Journal:  Mol Cell Endocrinol       Date:  2022-03-04       Impact factor: 4.369

4.  Interrelationship Between Vitamin D Insufficiency, Calcium Homeostasis, Hyperaldosteronism, and Autoimmunity.

Authors:  Decio Armanini; Alessandra Andrisani; Guido Ambrosini; Gabriella Donà; Valentina Camozzi; Luciana Bordin; Chiara Sabbadin
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-04-21       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.